亚洲免费av电影一区二区三区,日韩爱爱视频,51精品视频一区二区三区,91视频爱爱,日韩欧美在线播放视频,中文字幕少妇AV,亚洲电影中文字幕,久久久久亚洲av成人网址,久久综合视频网站,国产在线不卡免费播放

        ?

        Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

        2021-01-07 23:21:09EdwardWalshetal
        四川生理科學(xué)雜志 2021年1期

        Edward E Walsh, et al.

        Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and the resulting disease,coronavirus disease 2019 (Covid-19), have spread to millions of persons worldwide.Multiple vaccine candidates are under development, but no vaccine is currently available.Interim safety and immunogenicity data about the vaccine candidate BNT162b1 in younger adults have been reported previously from trials in Germany and the United States.

        Methods: In an ongoing, placebo-controlled, observer-blinded, dose-escalation, phase 1 trial conducted in the United States,we randomly assigned healthy adults 18 to 55 years of age and those 65 to 85 years of age to receive either placebo or one of two lipid nanoparticle-formulated, nucleoside-modified RNA vaccine candidates: BNT162b1, which encodes a secreted trimerized SARS-CoV-2 receptor-binding domain; or BNT162b2, which encodes a membrane-anchored SARS-CoV-2 full-length spike, stabilized in the prefusion conformation.The primary outcome was safety (e.g., local and systemic reactions and adverse events); immunogenicity was a secondary outcome.Trial groups were defined according to vaccine candidate, age of the participants, and vaccine dose level (10 μg, 20 μg, 30 μg, and 100 μg).In all groups but one, participants received two doses, with a 21-day interval between doses; in one group (100 μg of BNT162b1), participants received one dose.

        Results: A total of 195 participants underwent randomization.In each of 13 groups of 15 participants, 12 participants received vaccine and 3 received placebo.BNT162b2 was associated with a lower incidence and severity of systemic reactions than BNT162b1, particularly in older adults.In both younger and older adults, the two vaccine candidates elicited similar dose-dependent SARS-CoV-2-neutralizing geometric mean titers, which were similar to or higher than the geometric mean titer of a panel of SARS-CoV-2 convalescent serum samples.

        Conclusions: The safety and immunogenicity data from this U.S.phase 1 trial of two vaccine candidates in younger and older adults, added to earlier interim safety and immunogenicity data regarding BNT162b1 in younger adults from trials in Germany and the United States, support the selection of BNT162b2 for advancement to a pivotal phase 2-3 safety and efficacy evaluation.(Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).

        熟妇人妻中文字幕无码老熟妇| 国产精品黑丝美女av| 高潮av一区二区三区| 亚洲av午夜一区二区三| 高h小月被几个老头调教| 深夜福利小视频在线观看| 久久频精品99香蕉国产| 男女激情床上视频网站| 二区三区日本高清视频| 欧美精品无码一区二区三区| а√中文在线资源库| 欧洲熟妇色xxxxx欧美老妇伦| 人妻少妇被猛烈进入中文字幕 | 国产日韩久久久久69影院| 日韩精品国产精品亚洲毛片| 亚洲最新国产av网站| 97精品人人妻人人| 亚洲精品久久久久中文字幕二区| 精品 无码 国产观看| 熟女白浆精品一区二区| 三上悠亚亚洲精品一区| 亚洲精品无码久久久久y| 国产色xx群视频射精| 好大好深好猛好爽视频免费| 国产中出视频| 亚洲成人av一区二区三区| 国产人妖在线免费观看| 亚洲一区二区懂色av| 精品视频一区二区三区在线观看 | 色天使久久综合网天天| 日韩内射美女人妻一区二区三区| 国产在视频线精品视频二代| 人妖啪啪综合av一区| av无码国产精品色午夜| 亚洲av一宅男色影视| 欧洲亚洲视频免费| 亚洲天堂一区二区三区| 精品国产sm最大网站| 无码人妻丰满熟妇区毛片| 97超级碰碰碰久久久观看| 视频一区二区免费在线观看|